JP2020512338A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020512338A5 JP2020512338A5 JP2019552887A JP2019552887A JP2020512338A5 JP 2020512338 A5 JP2020512338 A5 JP 2020512338A5 JP 2019552887 A JP2019552887 A JP 2019552887A JP 2019552887 A JP2019552887 A JP 2019552887A JP 2020512338 A5 JP2020512338 A5 JP 2020512338A5
- Authority
- JP
- Japan
- Prior art keywords
- sdf
- medicament according
- subject
- kidney
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 22
- 208000017169 kidney disease Diseases 0.000 claims 6
- 210000003734 kidney Anatomy 0.000 claims 5
- 239000013598 vector Substances 0.000 claims 5
- 241000282326 Felis catus Species 0.000 claims 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 3
- 239000007972 injectable composition Substances 0.000 claims 3
- 102000006573 Chemokine CXCL12 Human genes 0.000 claims 2
- 108010008951 Chemokine CXCL12 Proteins 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 210000005084 renal tissue Anatomy 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- 206010058116 Nephrogenic anaemia Diseases 0.000 claims 1
- 208000033626 Renal failure acute Diseases 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
- 206010048302 Tubulointerstitial nephritis Diseases 0.000 claims 1
- 201000011040 acute kidney failure Diseases 0.000 claims 1
- 208000012998 acute renal failure Diseases 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 239000008365 aqueous carrier Substances 0.000 claims 1
- 231100000850 chronic interstitial nephritis Toxicity 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 208000028208 end stage renal disease Diseases 0.000 claims 1
- 201000000523 end stage renal failure Diseases 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 210000002783 mesonephros Anatomy 0.000 claims 1
- 239000013600 plasmid vector Substances 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022179063A JP2023015227A (ja) | 2017-03-30 | 2022-11-08 | 腎臓疾患の治療方法 |
| JP2025003602A JP2025069172A (ja) | 2017-03-30 | 2025-01-09 | 腎臓疾患の治療方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762478684P | 2017-03-30 | 2017-03-30 | |
| US62/478,684 | 2017-03-30 | ||
| PCT/US2018/025063 WO2018183625A1 (en) | 2017-03-30 | 2018-03-29 | Methods of treatment for kidney disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022179063A Division JP2023015227A (ja) | 2017-03-30 | 2022-11-08 | 腎臓疾患の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020512338A JP2020512338A (ja) | 2020-04-23 |
| JP2020512338A5 true JP2020512338A5 (enExample) | 2021-04-22 |
| JP7667539B2 JP7667539B2 (ja) | 2025-04-23 |
Family
ID=63678100
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019552887A Active JP7667539B2 (ja) | 2017-03-30 | 2018-03-29 | 腎臓疾患の治療方法 |
| JP2022179063A Pending JP2023015227A (ja) | 2017-03-30 | 2022-11-08 | 腎臓疾患の治療方法 |
| JP2025003602A Pending JP2025069172A (ja) | 2017-03-30 | 2025-01-09 | 腎臓疾患の治療方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022179063A Pending JP2023015227A (ja) | 2017-03-30 | 2022-11-08 | 腎臓疾患の治療方法 |
| JP2025003602A Pending JP2025069172A (ja) | 2017-03-30 | 2025-01-09 | 腎臓疾患の治療方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11229682B2 (enExample) |
| EP (1) | EP3600251A4 (enExample) |
| JP (3) | JP7667539B2 (enExample) |
| AU (1) | AU2018244776B2 (enExample) |
| CA (1) | CA3055761A1 (enExample) |
| WO (1) | WO2018183625A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018244776B2 (en) * | 2017-03-30 | 2023-12-14 | Wake Forest University Health Sciences | Methods of treatment for kidney disease |
| WO2019032930A1 (en) | 2017-08-11 | 2019-02-14 | Wake Forest University Health Sciences | USE OF CXCL12 FOR THERAPY AFTER SURGERY OF THE PROSTATE |
| KR102288446B1 (ko) * | 2018-12-28 | 2021-08-10 | 서울대학교산학협력단 | Cxcl12 검출용 제제를 포함하는 다낭신의 진단용 조성물 및 이의 이용 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2216630T3 (es) | 1998-09-09 | 2004-10-16 | Scios Inc | Metodos de tratar la hipertension dependiente de la sal. |
| CA2412436C (en) | 2000-06-05 | 2013-05-21 | The Trustees Of Columbia University In The City Of New York | Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury |
| WO2006124013A2 (en) * | 2004-04-30 | 2006-11-23 | Five Prime Therapeutics, Inc. | Novel stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof, and method of use |
| CN101287460B (zh) | 2005-08-17 | 2012-04-25 | 希尔氏宠物营养品公司 | 预防和治疗肾病的组合物 |
| ES2432395T3 (es) * | 2006-10-12 | 2013-12-03 | Ethicon, Inc. | Células derivadas de riñon y metodo de uso en la reparación y regeneración tisular |
| EP2117543A4 (en) * | 2007-02-01 | 2011-09-28 | Nephrogen Llc | POTENTIALIZATION OF THE IMPLANTATION OF STEM CELLS AND TREATMENT OF ORGAN DYSFUNCTION OR BODY INSUFFICIENCY |
| ES2520044T3 (es) * | 2007-03-30 | 2014-11-11 | The Cleveland Clinic Foundation | SDF-1 para su uso en el tratamiento de trastornos vasculares periféricos isquémicos |
| JP5248519B2 (ja) * | 2007-11-07 | 2013-07-31 | 小野薬品工業株式会社 | Ｓｄｆ−１を含有してなる徐放性組成物 |
| WO2009114826A2 (en) | 2008-03-13 | 2009-09-17 | Angiodynamics, Inc. | Treatment systems and methods for renal-related diseases |
| US9694055B2 (en) * | 2008-05-09 | 2017-07-04 | Wake Forest University Health Sciences | Renal tissue regeneration |
| JP5856059B2 (ja) | 2009-08-28 | 2016-02-09 | ザ クリーブランド クリニック ファウンデーション | 虚血組織を治療するためのｓｄｆ−１送達 |
| WO2015089396A1 (en) * | 2013-12-13 | 2015-06-18 | Mesoblast International Sarl | Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1 |
| US10420818B2 (en) | 2014-05-08 | 2019-09-24 | Wake Forest University Health Sciences | Methods of treating incontinence and other sphincter deficiency disorders |
| KR102314110B1 (ko) | 2014-09-16 | 2021-10-18 | 삼성디스플레이 주식회사 | 시각화 가속부를 포함하는 터치 표시 장치 |
| AU2018244776B2 (en) * | 2017-03-30 | 2023-12-14 | Wake Forest University Health Sciences | Methods of treatment for kidney disease |
-
2018
- 2018-03-29 AU AU2018244776A patent/AU2018244776B2/en active Active
- 2018-03-29 EP EP18777904.6A patent/EP3600251A4/en active Pending
- 2018-03-29 CA CA3055761A patent/CA3055761A1/en active Pending
- 2018-03-29 WO PCT/US2018/025063 patent/WO2018183625A1/en not_active Ceased
- 2018-03-29 US US16/496,117 patent/US11229682B2/en active Active
- 2018-03-29 JP JP2019552887A patent/JP7667539B2/ja active Active
-
2021
- 2021-12-14 US US17/644,244 patent/US20220105156A1/en active Pending
-
2022
- 2022-11-08 JP JP2022179063A patent/JP2023015227A/ja active Pending
-
2025
- 2025-01-09 JP JP2025003602A patent/JP2025069172A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jiang et al. | Biomimetic nanovesicles as a dual gene delivery system for the synergistic gene therapy of Alzheimer’s disease | |
| Torres-Espín et al. | Eliciting inflammation enables successful rehabilitative training in chronic spinal cord injury | |
| Best et al. | Safety and dosing of bevacizumab (avastin) for the treatment of recurrent respiratory papillomatosis | |
| JP2016040335A5 (enExample) | ||
| Liao et al. | New progress in angiogenesis therapy of cardiovascular disease by ultrasound targeted microbubble destruction | |
| Mai et al. | The post-cardiac arrest syndrome: A case for lung–brain coupling and opportunities for neuroprotection | |
| Duskey et al. | Current strategies for the delivery of therapeutic proteins and enzymes to treat brain disorders | |
| JP2025069172A (ja) | 腎臓疾患の治療方法 | |
| Chaudhary et al. | Nanotechnology and adeno-associated virus-based decorin gene therapy ameliorates peritoneal fibrosis | |
| SI2823048T1 (en) | A new drug delivery system based on JCV-VLP | |
| JP2022508609A5 (enExample) | ||
| CN110139668A (zh) | 一种预防和治疗肝纤维化的方法 | |
| Mi et al. | Constructed transferrin receptor-targeted liposome for the delivery of fluvoxamine to improve prognosis in a traumatic brain injury mouse model | |
| Ren et al. | Nebulized Lipid Nanoparticles Deliver mRNA to the Liver for Treatment of Metabolic Diseases | |
| WO2020023335A1 (en) | Inhibition of kidney disease relapse by targeted cytokine depletion | |
| Burkhart et al. | Accessing targeted nanoparticles to the brain: The vascular route | |
| JP2017531042A5 (enExample) | ||
| Casaca-Carreira et al. | Distribution and penetration of intracerebroventricularly administered 2′ OMePS oligonucleotide in the mouse brain | |
| Fitzgerald et al. | A subcutaneous, potent and durable RNAi platform targeting metabolic diseases, genes PCSK9, ApoC3 and ANGPLT3 | |
| Brazil | A barrier to progress: getting drugs to the brain | |
| CN103656639B (zh) | 不规则趋化因子的中和抗体用于制备消除糖尿病心肾功能损害不良代谢记忆的药物的用途 | |
| Averyanov et al. | Inhaled surfactant in patients with covid-19 who took high-flow oxygen: The results of a retrospective analysis | |
| Xanthos et al. | Magnetically targeted drug delivery during cardiopulmonary resuscitation and the post-resuscitation period | |
| CN103720714A (zh) | 一种制作灵长类动物视网膜色素变性疾病模型的方法 | |
| US20260130848A1 (en) | Methods and compositions for central nervous system (cns) drug delivery and treatment |